Figure 5
From: Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models
Efficacy data for SPI-1865 in human amyloid precursor protein (APP)-overexpressing transgenic mice. SPI-1865 was orally dosed once a day (QD) for six days in female Tg2576 mice. Tissues were harvested 24 hrs after the final dose. The levels of compound, β-amyloid (Aβ)38, Aβ40, Aβ42 were measured in brain and plasma. Aβ38, Aβ40, Aβ42 levels were also measured in cerebrospinal fluid (CSF). All values are graphed as % of vehicle control. *P-value < 0.01 based on analysis of variance (Dunnett's test).